CAG
PGNX

Csenge Advisory Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Csenge Advisory Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22
Closed – – 1739
2018
Q3 		$0 Buy
+22
New +$169 ﹤0.01% 1819

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Csenge Advisory Group's PGNX Position: Q4 2018 in Review

Csenge Advisory Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 22 shares.

Csenge Advisory Group first reported a position in PGNX in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

  • Csenge Advisory Group reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Csenge Advisory Group sold 22 Progenics Pharmaceuticals Inc shares in Q4 2018.
  • Csenge Advisory Group first reported a position in Progenics Pharmaceuticals Inc in Q3 2018 and held it in 1 quarter.
  • Csenge Advisory Group's Progenics Pharmaceuticals Inc position peaked at $0 in Q3 2018.
  • 150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.